Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence

Research output: Contribution to journalReview articlepeer-review

28 Downloads (Pure)

Abstract

In this critical review, we explore the study design, strengths, and limitations of landmark trial “Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence”. This trial was the first to directly compare two key treatment options for urge urinary incontinence – anticholinergic medication and intravesical botox, and still influences clinical guidelines a decade after publication. This non-inferiority, double-blinded, multi-centre randomised controlled trial administered Solifenacin or intra-detrusor botox to women, measuring outcomes six months post-treatment. Non-inferiority of the treatments was established, though Botox had a higher rate of retention and infection, with side effect profile rising as the key discriminator in selecting first-line therapy.

Original languageEnglish
Article number98
Number of pages4
JournalBMC Urology
Volume23
DOIs
Publication statusPublished - 24 May 2023

Keywords

  • urinary incontinence
  • Anticholinergic therapy
  • onabotulinumtoxinA

Fingerprint

Dive into the research topics of 'Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence'. Together they form a unique fingerprint.

Cite this